53MEDIUM

IIQ

INOVIQ LTD FPO [IIQ]
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Healthcare · ASX Small Cap
$0.3300 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical33
Catalyst55
Sentiment50
Fundamental77
Momentum49
Risk Gate50
Get alerts when IIQ's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track IIQ — Free

Active Signals

Bullish Signals

  • Drifting lower — down 7.0% over the last 5 days
  • Strong cash runway (11 quarters)
  • 4C filed 2026-01-28
  • Strong revenue growth (+35%)
  • EPS estimates revised downward (-6pts)
  • Near 52-week low (5% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +35% — the top line is moving in the right direction
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about IIQ
"What's driving IIQ's score?" "How does IIQ compare to peers?" "Key risks for IIQ?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change of Director's Interest Notice - Peter Gunzburg
NONE Change of Director's Interest Notice - Peter Gunzburg
NONE Change of Director's Interest Notice - Peter Gunzburg
MEDIUM Quarterly Business Update and Appendix 4C - December 2025
Announcement tone +5pts

Recent ASX Announcements

2026-03-12 Change of Director's Interest Notice - Peter Gunzburg
2026-03-02 Change of Director's Interest Notice - Peter Gunzburg
2026-02-22 Change of Director's Interest Notice - Peter Gunzburg
2026-02-17 Appendix 4D and FY26 Half Year Financial Report PRICE SENSITIVE
2026-01-28 Quarterly Business Update and Appendix 4C - December 2025 PRICE SENSITIVE

Key Metrics

$47.2M
Market Cap
155K
Avg Volume
1.2x
Vol Ratio
$0.32 — $0.69
52-Week Range
N/A
Short Interest
11 qtrs
Cash Runway
-34.7%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 80%
LLeader vs LaggardlaggardRS: -2
IInstitutional SponsorshipweakInst: 9%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #17 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:IIQ vs ATXIIQ vs PNVIIQ vs IMM
Scout Pro — Deeper Analysis for IIQ
Try Pro free for 30 days
Share this analysis

Track IIQ and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required